Advertisement

Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis

  • L. Yang
  • J. Yang
  • T. Pan
  • X. ZhongEmail author
Original Article

Abstract

Objective

This study aimed to investigate the effects of liraglutide on bone metabolism markers in rat models with glucocorticoid-induced osteoporosis (GIOP), including the effects on bone mass, bone tissue microstructure, bone biomechanics, and bone turnover markers.

Method

Thirty male Sprague–Dawley rats aged 8 weeks were randomly divided into three groups: the control group (n = 10) was intramuscularly injected with an equal volume of 0.9% sodium chloride, the dexamethasone group (n = 10) was intramuscularly injected with dexamethasone at 1 mg/kg (twice a week) to induce GIOP, the dexamethasone plus liraglutide group (n = 10) was subcutaneously injected with liraglutide at 200 μg/kg daily, simultaneously. The bilateral femurs and the fifth lumbar vertebrae were collected after 12 weeks to perform micro-computed tomography and bone biomechanical examinations. Also, tartrate-resistant acid phosphatase (TRACP), cross-linked carboxy-terminal telopeptide of type I collagen (CTX-I), alkaline phosphatase (ALP), and osteocalcin (OC) were tested.

Results

The bone mineral density (BMD), bone microstructure, and bone biomechanical markers reduced significantly in the dexamethasone group compared with the control group. The bone resorption indicators (TRACP and CTX-I) increased, while the bone formation indicators (ALP and OC) decreased. After liraglutide treatment, BMD, bone microstructure, and bone biomechanical markers improved significantly. Moreover, TRACP and CTX-I decreased significantly, while ALP and OC increased compared with the dexamethasone group.

Conclusions

Liraglutide improved BMD, bone microstructure, and bone strength and reversed GIOP, primarily through the reduction of bone resorption and promotion of bone formation.

Keywords

Bone biomechanics Glucocorticoid-induced osteoporosis Liraglutide Micro-CT 

Notes

Acknowledgements

This study was supported by the university natural science research fund of Anhui province (KJ2017A174).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Informed consent

Not applicable.

References

  1. 1.
    Drake MT, Clarke BL, Lewiecki EM (2015) The pathophysiology and treatment of osteoporosis. Clin Ther 37:1837–1850CrossRefGoogle Scholar
  2. 2.
    Weinstein RS (2011) Clinical practice. glucocorticoid-induced bone disease. N Engl J Med 365:62–70CrossRefGoogle Scholar
  3. 3.
    Kanazawa I (2017) Interaction between bone and glucose metabolism [Review]. Endocr J 64:1043–1053CrossRefGoogle Scholar
  4. 4.
    DeShields SC, Cunningham TD (2018) Comparison of osteoporosis in US adults with type 1 and type 2 diabetes mellitus. J Endocrinol Invest 41:1051–1060CrossRefGoogle Scholar
  5. 5.
    Hamilton EJ, Rakic V, Davis WA, Paul Chubb SA, Kamber N, Prince RL, Davis TM (2012) A five-year prospective study of bone mineral density in men and women with diabetes: the fremantle diabetes study. Acta Diabetol 49:153–158CrossRefGoogle Scholar
  6. 6.
    Rubin MR (2015) Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep 13:186–191CrossRefGoogle Scholar
  7. 7.
    Pereira M, Jeyabalan J, Jorgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME, Chenu C (2015) Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81:459–467CrossRefGoogle Scholar
  8. 8.
    Ma CC, Xu SQ, Gong X, Wu Y, Qi S, Liu W, Xu JH (2017) Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. Arch Osteoporos 12:33CrossRefGoogle Scholar
  9. 9.
    De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214CrossRefGoogle Scholar
  10. 10.
    Cairoli E, Palmieri S, Goggi G, Roggero L, Arosio M, Chiodini I, Eller-Vainicher C (2018) Denosumab or oral bisphosphonates in primary osteoporosis: a “real-life” study. J Endocrinol Invest 41:1005–1013CrossRefGoogle Scholar
  11. 11.
    Novelli M, De Tata V, Bombara M, Lorenzini A, Masini M, Pollera M, Bergamini E, Masiello P (1999) Insufficient adaptive capability of pancreatic endocrine function in dexamethasone-treated ageing rats. J Endocrinol 162:425–432CrossRefGoogle Scholar
  12. 12.
    Caperuto LC, Anhe GF, Amanso AM, Ribeiro LM, Medina MC, Souza LC, Carvalho OM, Bordin S, Saad MJ, Carvalho CR (2006) Distinct regulation of IRS proteins in adipose tissue from obese aged and dexamethasone-treated rats. Endocrine 29:391–398CrossRefGoogle Scholar
  13. 13.
    dos Santos C, Ferreira FB, Goncalves-Neto LM, Taboga SR, Boschero AC, Rafacho A (2014) Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats. Can J Physiol Pharmacol 92:867–878CrossRefGoogle Scholar
  14. 14.
    Chimin P, Farias Tda S, Torres-Leal FL, Bolsoni-Lopes A, Campana AB, Andreotti S, Lima FB (2014) Chronic glucocorticoid treatment enhances lipogenic activity in visceral adipocytes of male Wistar rats. Acta Physiol (Oxf) 211:409–420CrossRefGoogle Scholar
  15. 15.
    Gallwitz B (2005) Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 4:361–370CrossRefGoogle Scholar
  16. 16.
    Su B, Sheng H, Zhang M et al (2015) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine 48:107–115CrossRefGoogle Scholar
  17. 17.
    Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 100:2909–2917CrossRefGoogle Scholar
  18. 18.
    Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, Mabilleau G (2015) Stable incretin mimetics counter rapid deterioration of bone quality in type 1 Diabetes Mellitus. J Cell Physiol 230:3009–3018CrossRefGoogle Scholar
  19. 19.
    Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 28:1641–1652CrossRefGoogle Scholar
  20. 20.
    Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574–579CrossRefGoogle Scholar
  21. 21.
    Wen B, Zhao L, Zhao H, Wang X (2018) Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med 15:5077–5083Google Scholar
  22. 22.
    Montagnani A, Gonnelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 15:784–791CrossRefGoogle Scholar
  23. 23.
    Sun HX, Lu N, Luo X, Zhao L, Liu JM (2015) Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes 7:584–588CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  1. 1.Department of EndocrinologyThe Second Affiliated Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China

Personalised recommendations